Interpret the medical insurance reimbursement policy of Gefapixant Citrate

Gefapixant Citrate (Gefapixant Citrate) is a new antitussive drug mainly used to treat refractory or unexplained chronic cough in adults. The drug inhibits the cough reflex through a specific mechanism, providing patients with a new treatment option. However, the medical insurance reimbursement policy for Gemfapixin in China is still unclear because the original drug of this drug is not currently on the market in China. In view of this, we can only make predictions and analyzes based on the current situation.

First of all, the medical insurance reimbursement policy of Gifapixin is closely related to its domestic launch progress. If the drug is approved by the Chinese Food and Drug Administration and officially launched on the market, whether it can be included in the scope of medical insurance reimbursement will still need to be determined based on its efficacy, price, market demand, and national medical insurance policies. Generally speaking, after new drugs enter the Chinese market, their clinical value and economic benefits will first be evaluated by relevant agencies. If Gemfapixin can show significant therapeutic effects, especially for patients with refractory or unexplained chronic cough, and can effectively reduce patients’ symptoms and improve their quality of life, then it is more likely to be included in medical insurance.

However, drug prices are an important factor affecting medical insurance reimbursement. If the price of Gemfapixin is relatively high and its cost-effectiveness compared with existing treatments fails to meet certain standards, it may face difficulties in medical insurance approval. In some foreign countries, the therapeutic effect of Gemfapixin has been verified, but the high price of the drug is still an obstacle to its widespread application.

In short, the medical insurance reimbursement policy for Gifapixin has not yet been formally established in China, but with the progress of drug launch and changes in market demand, we can look forward to the introduction of relevant policies in the future. Patients and medical staff can pay attention to the launch progress of drugs and relevant notices from the medical insurance department to keep up to date with the latest reimbursement information.

Reference materials:https://www.medicines.org.uk/emc/product/15778/pil